Direct binding of hepatocyte growth factor and vascular endothelial growth factor to CD44v6

Volz Y, Koschut D, Matzke-Ogi A, Dietz MS, Karathanasis C, Richert L, Wagner MG, Mely Y, Heilemann M, Niemann H, Orian-Rousseau V (2015)
Bioscience Reports 35(4): e00236.

Download
No fulltext has been uploaded. References only!
Journal Article | Original Article | Published | English

No fulltext has been uploaded

Author
; ; ; ; ; ; ; ; ; ;
Abstract
CD44v6, a member of the CD44 family of transmembrane glycoproteins is a co-receptor for two receptor tyrosine kinases (RTKs), Met and VEGFR-2 (vascular endothelial growth factor receptor 2). CD44v6 is not only required for the activation of these RTKs but also for signalling. In order to understand the role of CD44v6in Met and VEGFR-2 activation and signalling we tested whether CD44v6 binds to their ligands, HGF (hepatocyte growth factor) and VEGF (vascular endothelial growth factor), respectively. FACS analysis and cellular ELISA showed binding of HGF and VEGF only to cells expressing CD44v6. Direct binding of CD44v6 to HGF and VEGF was demonstrated in pull-down assays and the binding affinities were determined using MicroScale Thermophoresis, fluorescence correlation spectroscopy and fluorescence anisotropy. The binding affinity of CD44v6 to HGF is in the micromolar range in contrast with the high-affinity binding measured in the case of VEGF and CD44v6, which is in the nanomolar range. These data reveal a heparan sulfate-independent direct binding of CD44v6 to the ligands of Met and VEGFR-2 and suggest different roles of CD44v6 for these RTKs.
Keywords
Publishing Year
ISSN
eISSN
PUB-ID

Cite this

Volz Y, Koschut D, Matzke-Ogi A, et al. Direct binding of hepatocyte growth factor and vascular endothelial growth factor to CD44v6. Bioscience Reports. 2015;35(4): e00236.
Volz, Y., Koschut, D., Matzke-Ogi, A., Dietz, M. S., Karathanasis, C., Richert, L., Wagner, M. G., et al. (2015). Direct binding of hepatocyte growth factor and vascular endothelial growth factor to CD44v6. Bioscience Reports, 35(4), e00236. doi:10.1042/BSR20150093
Volz, Y., Koschut, D., Matzke-Ogi, A., Dietz, M. S., Karathanasis, C., Richert, L., Wagner, M. G., Mely, Y., Heilemann, M., Niemann, H., et al. (2015). Direct binding of hepatocyte growth factor and vascular endothelial growth factor to CD44v6. Bioscience Reports 35:e00236.
Volz, Y., et al., 2015. Direct binding of hepatocyte growth factor and vascular endothelial growth factor to CD44v6. Bioscience Reports, 35(4): e00236.
Y. Volz, et al., “Direct binding of hepatocyte growth factor and vascular endothelial growth factor to CD44v6”, Bioscience Reports, vol. 35, 2015, : e00236.
Volz, Y., Koschut, D., Matzke-Ogi, A., Dietz, M.S., Karathanasis, C., Richert, L., Wagner, M.G., Mely, Y., Heilemann, M., Niemann, H., Orian-Rousseau, V.: Direct binding of hepatocyte growth factor and vascular endothelial growth factor to CD44v6. Bioscience Reports. 35, : e00236 (2015).
Volz, Yvonne, Koschut, David, Matzke-Ogi, Alexandra, Dietz, Marina S., Karathanasis, Christos, Richert, Ludovic, Wagner, Moritz G., Mely, Yves, Heilemann, Mike, Niemann, Hartmut, and Orian-Rousseau, Veronique. “Direct binding of hepatocyte growth factor and vascular endothelial growth factor to CD44v6”. Bioscience Reports 35.4 (2015): e00236.
This data publication is cited in the following publications:
This publication cites the following data publications:

5 Citations in Europe PMC

Data provided by Europe PubMed Central.

Differential recruitment of CD44 isoforms by ErbB ligands reveals an involvement of CD44 in breast cancer.
Morath I, Jung C, Lévêque R, Linfeng C, Toillon RA, Warth A, Orian-Rousseau V., Oncogene 37(11), 2018
PMID: 29321661
Serglycin in tumor microenvironment promotes non-small cell lung cancer aggressiveness in a CD44-dependent manner.
Guo JY, Hsu HS, Tyan SW, Li FY, Shew JY, Lee WH, Chen JY., Oncogene 36(17), 2017
PMID: 27819672
CAR T-cell immunotherapy of MET-expressing malignant mesothelioma.
Thayaparan T, Petrovic RM, Achkova DY, Zabinski T, Davies DM, Klampatsa A, Parente-Pereira AC, Whilding LM, van der Stegen SJ, Woodman N, Sheaff M, Cochran JR, Spicer JF, Maher J., Oncoimmunology 6(12), 2017
PMID: 29209570
The prognostic value and clinicopathological significance of CD44 expression in ovarian cancer: a meta-analysis.
Zhao L, Gu C, Huang K, Zhang Z, Ye M, Fan W, Han W, Meng Y., Arch Gynecol Obstet 294(5), 2016
PMID: 27300001
Expression and Function of CD44 in Epithelial Ovarian Carcinoma.
Sacks JD, Barbolina MV., Biomolecules 5(4), 2015
PMID: 26569327

Export

0 Marked Publications

Open Data PUB

Web of Science

View record in Web of Science®

Sources

PMID: 26181364
PubMed | Europe PMC

Search this title in

Google Scholar